## **Abstract**

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof

$$R_1$$
  $N$   $R_2$   $G$   $G$   $G$ 

wherein

the dashed line may represent a double bond;

R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:

halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O) $R_2$ , nitro, hydroxy, -NR<sub>3</sub>R<sub>4</sub>, cyano and or a group Z;

R<sub>1</sub> is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, halogen, NR<sub>3</sub>R<sub>4</sub> or cyano;

 $R_2$  is a C1-C4 alkyl,  $-OR_3$  or  $-NR_3R_4$ ;

R<sub>3</sub> is hydrogen or C1-C6 alkyl;

R<sub>4</sub> is hydrogen or C1-C6 alkyl;

R<sub>5</sub> is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR<sub>3</sub>R<sub>4</sub>; -C(O)R<sub>2</sub>;

R<sub>6</sub> is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR<sub>3</sub>R<sub>4</sub>; -C(O)R<sub>2</sub>;

R<sub>7</sub> is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;

R<sub>8</sub> is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR<sub>3</sub>R<sub>4</sub> or cyano;

R<sub>9</sub> is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR<sub>3</sub>R<sub>4</sub> or cyano;

R<sub>10</sub> is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR<sub>3</sub>R<sub>4</sub> or cyano;

R<sub>11</sub> is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR<sub>3</sub>R<sub>4</sub> or cyano;

 $R_{12}$  is  $R_3$  or  $-C(O)R_2$ ;

D is CR<sub>8</sub>R<sub>9</sub> or is CR<sub>8</sub> when double bonded with G;

## PB60162A

G is CR<sub>10</sub>R<sub>11</sub> or is CR<sub>10</sub> when double bonded with D or is CR<sub>10</sub> when double bonded with X when X is carbon;

X is carbon or nitrogen; Y is nitrogen or -CR<sub>7</sub>;

Y is nitrogen or -CR<sub>7</sub>; W is a 4-8 membered ring, which may be saturated or may

contain one to three double bonds, and

## in which:

- one carbon atom is replaced by a carbonyl or S(O)<sub>m</sub>; and
- one to four carbon atoms may optionally be replaced by oxygen, nitrogen or  $NR_{12}$ ,  $S(O)_m$ , carbonyl, and such ring may be further substituted by 1 to 8  $R_6$  groups;
- z is a 5-6 membered heterocycle, which may be substituted by 1 to 8  $R_5$  groups or a phenyl ring, which may be substituted by 1 to 4  $R_5$  groups;

m is an integer from 0 to 2.

to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).